Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Precancerous Conditions 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Tongue Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Gliosarcoma 1Glioblastoma 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma, Basal Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Bile Duct Neoplasms 1Basal Cell Nevus Syndrome 1

Interventions

Temozolomide 48Radiotherapy 26Radiation 13Chemotherapy, Adjuvant 9O(6)-benzylguanine 8Irinotecan 8Carmustine 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6motexafin gadolinium 5Radiotherapy, Intensity-Modulated 5Imatinib Mesylate 5sargramostim 4Radiotherapy, Conformal 4Hydroxyurea 4Gene Expression Profiling 4lonafarnib 3Radiosurgery 3Immunohistochemistry 3Genetic Therapy 3Filgrastim 3Drug Therapy 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2tipifarnib 2temsirolimus 2cediranib 2aldesleukin 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Gliosarcoma × Microarray Analysis × Clear all
NCT00387400 2023-08-04

Temozolomide + Everolimus in Newly Diagnosed, Recurrent, or Progressive Malignant Glioblastoma Multiforme

Canadian Cancer Trials Group

Phase 1 Completed
32 enrolled
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡